Improving arteriovenous fistula patency: Transdermal delivery of diclofenac reduces cannulation-dependent neointimal hyperplasia via AMPK activation

MacAskill, Mark G.; Watson, David; Ewart, Marie-Ann; Wadsworth, R. M.; Jackson, Andrew; Aitken, Emma; MacKenzie, Graeme; Kingsmore, David; Currie, Susan; Coats, Paul

doi:10.1016/j.vph.2015.02.012

Cited by 5 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MacAskill et al and Kim et al stated in their studies that preexisting or incoming intimal hyperplasia was an important factor in AVF survival. On the other hand, the existence or absence of arteriosclerosis in the artery used for anastomosis was considered, which is similar to the study of Parmer et al, both on physiological and mechanical basis [6,11,12,15] .…”

Section: Discussionmentioning

confidence: 78%

“…Also, immediate and long-term success of a newly constructed AVF depends on several hemodynamic factors, vessel characteristics, and surgeon experience [3][4][5][6][7][8][9][10][11][12][13][14][15][16] . MacAskill et al and Kim et al stated in their studies that preexisting or incoming intimal hyperplasia was an important factor in AVF survival.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of Intraoperative and 24h Blood Pressure Levels and Presence of Arteriosclerosis on Arteriovenous Fistula

Güneş¹

2019

Haydarpasa Numune Med J

View full text Add to dashboard Cite

Introduction: Creation and subsequent patency of arteriovenous fistula (AVF) is crucial for hemodialysis patients. Early thrombosis is one of the main reasons of fistula occlusion. This study aimed to explore the effect of blood pressure and the presence of visible arteriosclerosis in the artery used for anastomosis on the patency of AVF. Methods: This retrospective study AVF was created in 231 consecutive patients. We used the Brecio-Cimino technique to create AVF in 50% of patients. Perioperative systolic (SBP) and diastolic (DBP) blood pressures were recorded just before declampage and during the following 24-h period for each 6-h intervals. Age, gender, presence of macroscopic arteriosclerosis in the artery used for an astomosis, and the etiologic factors of chronic renal failure parameters were all equally recorded. Results: The overall early fistula survival rate was 83%. No statistically significant immediate fistula dysfunction in terms of blood pressure differences was found. The multivariate analysis of the factors related to the AV fistula in the first 24 h patency revealed that only upper arm fistula was more likely effective (OR=1.192, p=0.003). Discussion and Conclusion: The effect of age, gender, presence of arteriosclerosis, and the history of existence of central venous catheter on early AVF patency was not observed. The rate of fistula patency was higher in the upper arm compared to fistulas in the lower arm. No significant difference concerning AVF patency was observed between patients with arterial blood pressure higher or lower than 120 mmHg.

show abstract

Section: Discussionmentioning

confidence: 78%

Section: Discussionmentioning

confidence: 99%

Impact of Intraoperative and 24h Blood Pressure Levels and Presence of Arteriosclerosis on Arteriovenous Fistula

Güneş¹

2019

Haydarpasa Numune Med J

View full text Add to dashboard Cite

show abstract

“…It is known that the activation of the ERK1/2 pathway in SMCs contributes to AVF stenosis [ 22 ]. Thus, we investigated whether Gal-3 can activate ERK1/2 pathway in SMCs.…”

Section: Resultsmentioning

confidence: 99%

Effect of galectin-3 in the pathogenesis of arteriovenous fistula stenosis formation

Ruan

Yao

et al. 2021

Renal Failure

View full text Add to dashboard Cite

Objective This study sought to investigate the effect of local expression of galectin-3 in the development of stenotic arteriovenous fistula (AVF). Methods We collected stenotic venous tissues, adjacent nonstenotic venous tissues, and blood samples from end-stage renal disease (ESRD) patients with AVF stenosis, while normal venous tissues and blood samples were collected from ESRD patients before AVF creation as controls. Also blood samples were collected from ESRD patients with nonstenosis functional AVF. Galectin-3, proliferating cell nuclear antigen (PCNA), matrix metalloproteinase-9 (MMP-9), and α-SMA expression in the venous tissues were examined by immunohistochemistry, and the ERK1/2 pathway activity in the intima was accessed by western blot. Serum galectin-3 level was measured by ELISA. Thereafter, human pulmonary arterial smooth muscle cells (HPASMCs) were cultured in vitro , and the interaction between Galectin-3 and ERK1/2 pathway in HPASMCs was estimated by western blot. Results ESRD patients with stenotic AVF had a significant higher serum galectin-3 level than normal controls, and patients with non-stenotic functional AVF. The expression levels of galectin-3, phosphorylated ERK1/2, PCNA, MMP-9, and α-SMA in the stenotic venous tissues were higher than that in the normal venous tissues or the adjacent nonstenotic AVF venous tissues. Correlation analysis showed that the expression of galectin-3 of the neointima was positively correlated with PCNA and α-SMA in the stenotic AVF venous tissues. In HPASMCs, galectin-3 can increase the activity of phosphorylated ERK1/2 and promote the expression of α-SMA. Conclusion In the stenotic AVF of ESRD patients, expression of the galectin-3 was significantly increased, showing a positive relation with neointima development.

show abstract

“…Cilostazol decreases the intracellular concentration of calcium, which causes cellular relaxation. Additionally, cilostazol can directly suppress the proliferation of vascular smooth muscle cells by E2F downregulation or as a response to platelet-derived growth factor (PDGF) (MacAskill et al, 2015). Cilostazol can improve endothelial cell function by increasing nitric oxide production and decreasing inflammatory responses in endothelial cells.…”

Section: Discussionmentioning

confidence: 99%

On a quest to prevent harm and safeguard paediatric venous catheters – A randomized control trial protocol

Charters,

Foster,

Lawton

et al. 2022

Vasc Acc

View full text Add to dashboard Cite

Aim: This study will evaluate the most effective peripheral intravenous catheter securement in paediatric emergency departments to reduce catheter failure, healthcare costs, patient distress, and improve satisfaction. Design: A multisite, three-arm, parallel, superiority, randomized controlled trial of 506 children requiring peripheral intravenous catheter in the emergency department. The trial will be reported following CONSORT guidelines, is registered on the Australian New Zealand Clinical Trials Registry (ACTRN12619001026112) and ethics is approved via Children’s Health Queensland Hospital and Health Service Human Research Ethics Committee (HREC/19/QCHQ/45567). Methods: Staff screen patients, six months to eight years old, requiring peripheral intravenous catheters and inpatient stay of more than 24 hours. Written informed consent is obtained from the legal guardian with 1:1:1 randomization ratio allocation: 1. Standard care: Bordered polyurethane dressing (Tegaderm Advanced®; 3M) 2. Integrated dressing and securement: SorbaView SHIELD® (Centurion Medical Products) 3. Integrated dressing and securement with tissue adhesive: SorbaView SHIELD® (Centurion Medical Products) and Tissue Adhesive Secureport IVTM (Adhezion Biomedical) Primary outcome is peripheral intravenous catheter failure; secondary outcomes are peripheral intravenous catheter complications, pain and distress, healthcare costs, and staff satisfaction or acceptability. Intention-to-treat analysis of timeto-event data will be completed using adjusted Cox regression. Direct costs calculated from the hospital perspective and costeffectiveness analysis will estimate the incremental cost of each treatment option. Discussion: Most hospitalized children require a peripheral intravenous catheter, although persistent high rates of failure are recognized as a patient safety concern. The outcomes of this trial will directly inform clinical care for peripheral intravenous catheter securement in children in emergency departments. Charters1,2, RN, PG Paed Acute Care, Kelly Foster2 , MNRS, RN, Dip HS, PG Crit Care, PhD Candidate, Benjamin Lawton1 , BSc, MBCHB, FRACP, Mph, Corey Cassidy3 , BSc (Hons), MBBS (Hons), FACEM, Joshua Byrnes4 , BEcon, BComm, MEcon, MHealth Econ, PhD, Gabor Mihala4,5, MEng (Mech), Gcert (Biostat), PhD, Jessica Schults5-8, RN, PhD, Tricia Kleidon5,6,8, RN, MNSci (Nurse Prac.), PhD candidate, Ruth McCaffery3 , RN, Kristy Van9 , RN, MNrs, and Amanda Ullman5-8, RN, PhD

show abstract

Improving arteriovenous fistula patency: Transdermal delivery of diclofenac reduces cannulation-dependent neointimal hyperplasia via AMPK activation

Cited by 5 publications

References 29 publications

Impact of Intraoperative and 24h Blood Pressure Levels and Presence of Arteriosclerosis on Arteriovenous Fistula

Impact of Intraoperative and 24h Blood Pressure Levels and Presence of Arteriosclerosis on Arteriovenous Fistula

Effect of galectin-3 in the pathogenesis of arteriovenous fistula stenosis formation

On a quest to prevent harm and safeguard paediatric venous catheters – A randomized control trial protocol

Contact Info

Product

Resources

About